Physician profile
John Custer
NPI 1578679452
$3,464.22
in general payments reported to CMS, 2019-2025
18 companies · $570 in 2025
The $570 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $136 · 2021: $385 · 2022: $529 · 2023: $1,049 · 2024: $644 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $657.70 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $525.93 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $455.31 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $376.64 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $329.14 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $311.89 | 2023-2024 | Auvelity |
| Abbvie INC. | $176.05 | 2021-2025 | Vraylar |
| Indivior INC. | $143.66 | 2020-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $117.36 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $88.04 | 2019-2024 | Ingrezza |
| Eisai INC. | $71.62 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.66 | 2022-2025 | Caplyta |
| Noven Therapeutics, LLC | $41.74 | 2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $32.11 | 2023 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $26.42 | 2025 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $22.11 | 2019 | |
| Merck Sharp & Dohme LLC | $12.74 | 2022 | |
| Allergan, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Custer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.